Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra (Kineret) in Patients With Still's Disease (SJIA and AOSD)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Adult-onset Still's disease; Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms anaSTILLs
- Sponsors Swedish Orphan Biovitrum
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 24 Apr 2019 Status changed from recruiting to discontinued, according to the Swedish Orphan Biovitrum media release.
- 24 Apr 2019 According to the Swedish Orphan Biovitrum media release, after careful consideration and evaluation company decided to end enrolment and discontinue the study. The study will be completed according to plan for the patients enrolled.